Hydroxychloroquine for Covid-19: No Benefit in New Open-label, Randomized Trial

[Preprint] Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial – medRxiv

See also just published observational study (Preprint): No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial – medRxiv

Related Commentary on Twitter

#COVID19 Here comes another dataset of #Hydroxychloroquine from an open-label randomized controlled trial in Chinahttps://t.co/qW93wMDILK

No difference in 28-day #coronavirus negative conversion rate for HCQ + SOC vs SOC

No difference in 28-day symptoms alleviation rate either pic.twitter.com/pOsBSQWeuO

— Andy Biotech (@AndyBiotech) April 14, 2020